Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-dp is indicated for: primary treatment of ovarian cancer in combination with a platinum agent.; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-dp is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-dp is indicated for the treatment of : primart treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - paclitaxel-dp is indicated for: primary treatment of ovarian cancer in combination with a platinum agent ; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil; citric acid - paclitaxel agila is indicated for: primary treatment of ovarian cancer in combination with a platinum agent.; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil; citric acid - paclitaxel agila is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy. * adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. * treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil; citric acid - paclitaxel agila is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: citric acid; ethanol absolute; peg-35 castor oil - paclitaxel an is indicated for: primary treatment of ovarian cancer in combination with a platinum agent.; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: peg-35 castor oil; ethanol absolute; citric acid - paclitaxel an is indicated for the treatment of : primart treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; citric acid; peg-35 castor oil - paclitaxel an is indicated for: primary treatment of ovarian cancer in combination with a platinum agent ; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.